H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on ACRV stock, giving a Buy rating yesterday.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar’s rating is based on the promising clinical data and strategic advancements of Acrivon Therapeutics, Inc. The company has shown encouraging results in its Phase 2 trials for ACR-368 in endometrial cancer, with a confirmed objective response rate of 35% in biomarker-positive patients, which is significantly higher than the typical response rates for second-line therapies. This indicates a potential superiority over the standard of care chemotherapy treatments.
Furthermore, Acrivon’s ongoing Phase 1 trial of ACR-2316 has demonstrated early clinical activity, including tumor shrinkage in various solid tumors. The company’s strategic decision to enroll patients without the need for pre-treatment biopsies in their Phase 2b trial could streamline the process and make it more appealing to patients and clinicians. This approach, combined with the company’s plans to share further data updates, supports the positive outlook and Buy rating given by Emily Bodnar.